Latest News
Moberg Pharma reports new Phase 3 analyses on terbinafine activity in onychomycosis
5 October 2026 - Swedish pharmaceutical company Moberg Pharma AB (STO: MOB) on Monday announced that it has published new analyses showing potent antifungal activity of terbinafine against dermatophytes causing onychomycosis.The company said its topi...
AstraZeneca completes USD2bn equity investment in Summit Therapeutics
5 October 2026 - Biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (NYSE:AZN) said on Monday that it has completed a USD2bn strategic equity investment in biopharmaceutical oncology company Summit Therapeutics Inc (NASDAQ:SMMT) to support...
GE HealthCare to acquire SOFIE Biosciences for USD945m
5 October 2026 - Medical technology company GE HealthCare (Nasdaq:GEHC) announced on Monday that it has agreed to acquire SOFIE Biosciences from Trilantic North America for USD945m in cash, expanding its US radiopharmaceutical manufacturing footprint...
FDA approves second Reykjavik manufacturing suite for AVT02
5 October 2026 - Global biotechnology company Alvotech (NASDAQ: ALVO; STO: ALVO-SDB), which develops and manufactures biosimilar medicines, said on Monday it has received US Food and Drug Administration approval for a supplement to the Biologics Lice...
Ractigen Therapeutics reports positive first-in-human data for RAG-18 in Duchenne muscular dystrophy
5 October 2026 - Ractigen Therapeutics, a China-based, clinical-stage biotechnology company, announced on Saturday the presentation of positive first-in-human clinical data from its ongoing Phase I trial of RAG-18 during a Late-Breaking Oral Presenta...